Cytori Therapeutics, Inc. (CYTX.O)
5.77USD
2:47pm EST
$-0.42 (-6.79%)
$6.19
$6.23
$6.23
$5.67
833,906
894,098
$6.65
$1.42
CYTX.O
About
Overall
| Beta: | 1.99 |
| Market Cap (Mil.): | $234.85 |
| Shares Outstanding (Mil.): | 38.75 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| CYTX.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.54 | 4.61 |
| EPS (TTM): | 53.36 | -- | -- |
| ROI: | -106.52 | 1.79 | 2.83 |
| ROE: | -- | 2.40 | 3.59 |
Athersys inks deal with Pfizer on stem-cell therapy
(Reuters) - Athersys Inc said it sold the rights of its stem-cell therapy to treat inflammatory bowel disease to Pfizer Inc, the world's biggest drugmaker, and shares of Athersys nearly doubled in value.
UPDATE 2-Athersys inks deal with Pfizer on stem-cell therapy
* Athersys to receive milestone payments of up to $105 mln
FACTBOX-Embryonic stem cells, the ultimate master cell
Dec 2 (Reuters) - The U.S. government approved the first 13 new batches of human embryonic stem cells on Wednesday, opening their use for federally funded research under reduced restrictions announced by President Barack Obama in March. [ID:nN028145]
FACTBOX: Embryonic stem cells, the ultimate master cell
(Reuters) - The U.S. National Institutes of Health released final rules on Monday governing federal funding of human embryonic stem cell research.
FACTBOX-Embryonic stem cells, the ultimate master cell
(For a story on the stem cell rules, click on [ID:nN06264664])
GE teams up with Geron for stem-cell research
BOSTON (Reuters) - General Electric Co is teaming up with U.S. biotech company Geron Corp to use stem cells to develop products that could give drug developers an early warning of whether new medicines are toxic.
UPDATE 4-GE teams up with Geron for stem-cell research
* Products would be used to test developing drug safety
UPDATE 1-Cytori Q1 loss narrows, backs '09 revenue view
BANGALORE, May 11 (Reuters) - Cytori Therapeutics Inc reported a narrower first-quarter loss, helped by lower total operating expenses and shares of the company rose as much as 39 percent.
UPDATE 2-Deals of the day -- mergers and acquisitions
May 8 (Reuters) - The following bids, mergers, acquisitions and disposals involving European, U.S. and Asian companies were reported by 2000 GMT on Friday.
HEADLINE STOCKS-U.S. stocks on the move on May 8
(Updates to add Cytori, Assured Guaranty, International Rectifier, CBS Corp)
Competitors
| Price | Change | |
|---|---|---|
| Medtronic, Inc. (MDT.N) | $43.42 | +0.20 |
| Baxter International Inc. (BAX.N) | $58.16 | +0.56 |
| Genzyme Corporation (GENZ.OQ) | $47.69 | -1.10 |
| Osiris Therapeutics, Inc. (OSIR.OQ) | $6.90 | -0.07 |
| Geron Corporation (GERN.OQ) | $5.65 | +0.15 |
| StemCells, Inc. (STEM.OQ) | $1.29 | +0.08 |
| Aastrom Biosciences, Inc. (ASTM.OQ) | $0.29 | +0.01 |
| Isolagen, Inc. (ILEIQ.PK) | -- | -- |
| Bioheart, Inc. (BHRT.OB) | $0.75 | 0.00 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
